$1.18
2.08%
Nasdaq, Oct 20, 02:26 pm EDT. Market open.
ISIN
US57055L1070
Symbol
MRKR

Marker Therapeutics, Inc. Stock price

$1.20
+0.00 0.00% 1M
-0.47 28.14% 6M
-0.29 19.46% YTD
+0.17 16.50% 1Y
-2.04 62.96% 3Y
-14.20 92.21% 5Y
-44.80 97.39% 10Y
+1.10 1,100.00% 20Y
Nasdaq, Closing price Mon, Oct 19 2026
+0.16 15.38%
ISIN
US57055L1070
Symbol
MRKR
Industry

Is Marker Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$20.0m
Enterprise Value
$8.7m
Net debt
positive
Cash
$11.3m
Shares outstanding
16.7m
Valuation
P/E
-
P/S | estimate
- | 4.6
EV/Sales | estimate
- | 2.0
EV/FCF | ex SBC
negative | negative
P/B
1.6
Financial Health
Equity Ratio
88.1%
Return on Equity
-72.4%
ROCE
-
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$520.0k | -
SBC as % of FCF
-
SBC Growth 1Y
4.0%
Share Count Growth 1Y
47.8%
Shareholder Yield
-47.8%
Financials
Revenue | estimate
- | $4.3m
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
$-9.8m | $-10.3m
Growth
Revenue | estimate
- | 21.9%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
10.4%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
$-0.6
Short interest
1.3%
Employees
5
Rev per Employee
$710.0k

Marker Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Marker Therapeutics, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Marker Therapeutics, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Marker Therapeutics, Inc.

Dec '25
+/-
%
3.55 3.55
46% 46%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.18 4.18
1% 1%
118%
- Research and Development Expense 12 12
12% 12%
332%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
12% 12%
-350%
Net Profit -12 -12
13% 13%
-343%

In millions USD.

Don't miss a Thing! We will send you all news about Marker Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Marker Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
●
one day ago
HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded $2.6 million from the U.S. Food and Drug Administration...
Neutral
GlobeNewsWire
●
28 days ago
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel...

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Head office United States
CEO Dr. Vera
Employees 5
Founded 1991
Website markertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today